Categories: Uncategorized

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment


The background

It is believed that a decrease in the frequency of basal insulin injections may lead to ease of treatment acceptance and adherence in patients with type 2 diabetes. Insulin iccode is a basal insulin analog designed for once-weekly administration that is under development for the treatment of diabetes.


We conducted a 26-week, randomized, double-blind, double-dummy to examine the efficacy and safety of the once-weekly insulin Himodac compared to the once-daily insulin glargine U100 in never-before-receiving patients. , Phase 2 tested. The term insulin treatment and whose type 2 diabetes were insufficiently controlled (glycated hemoglobin levels, 7.0 to 9.5%), while taking metformin with or without divertipidyl peptidase 4 inhibitor. The primary end point was the change in glycated hemoglobin level from baseline to week 26. Safety end points, including episodes of hypoglycemia and insulin-related adverse events, were also evaluated.


A total of 247 participants were randomly assigned (1: 1) to receive icodec or glargine. The basic characteristics were similar in the two groups; The mean basin glycated hemoglobin level was 8.09% in the icodec group and 7.96% in the glarine group. The estimated mean change from baseline in glycated hemoglobin levels was estimated at 1.1.33 percentage points in the icodec group and ec1.15 percentage points in the glargine group, 2669% and 6.20%, respectively, at 26 weeks; The estimated difference in change from baseline was .10.18 percentage points (95% CI, –0.38 to 0.02, P = 0.08). The observed rates of hypoglycemia with severity of level 2 (blood glucose level,

The conclusion

One-time weekly treatment with insulin icode had glucose-lowering efficacy and a safety profile similar to once-daily insulin glargine U100 in patients with type 2 diabetes. (Funded by Novo Nordisk; NN1436-4383 ClinicalTirales.GO no. NCT03751657.)

Quickly click the video
Once-weekly insulin for type 2 diabetes

Source link


Published by

Recent Posts

Environmental Factor – August 2017: Remembering children’s health champion Herbert Needleman

Herbert Needleman, MD, a physician-scientist whose lead in consumer products was removed due to research…

1 month ago

Environmental Factor – August 2017: FARE awards recognize 17 NIEHS fellows for outstanding research

ਸਤਾਰਾਂ ਐਨਆਈਈਐਚਐਸ ਫੈਲੋਜ਼ ਨੂੰ 199 ਨੈਸ਼ਨਲ ਇੰਸਟੀਚਿ ofਟ ਆਫ਼ ਹੈਲਥ (ਐਨਆਈਐਚ) ਦੇ ਖੋਜਕਰਤਾਵਾਂ ਵਿੱਚ ਖੋਜ…

1 month ago

Extramural Papers of the Month

(ਹੋਰ ਪੜ੍ਹੋ) Source link

1 month ago

Environmental Factor – January 2021: Woychik shares leadership philosophy and goals

In this inaugural director’s column, I would like to share with you what makes me…

1 month ago

Induction of Fetal Hemoglobin by Gene Therapy

Shortly after birth, fetal hemoglobin is replaced by adult hemoglobin in red cells, a process…

1 month ago

Treatment by CRISPR-Cas9 Gene Editing — A Proof of Principle

As a tool of great promise for the treatment of inherited human diseases, the clustered…

1 month ago